AbbVie scores key EU backing for Hepatitis C drug in push for earlier treatment

If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial

EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate

If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings

EU regulator backs Allergan Aesthetics’ Boey in key step toward approval

The decision marks a key step in the centralized EU review process

Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal

SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Africa CDC warns of regional Ebola spread risk as DRC and Uganda confirm outbreaks

Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration